Phase 3 N=34 Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers
Diabetic Foot Ulcer · Deep Diabetic Foot Ulcer
Primary: Wound Area at 16 Weeks — 6.1; 6.8 cm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Biobehavioral Mechanisms of Glucose Variability
Diabetes Mellitus, Type 1
Primary: Change Between Pre and Post Challenge Glucose Variability — 0.51; 1.62; 3.71; 0.97 score on a scale
Phase 3 N=31 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
Binge-Eating Disorder · Obesity
Primary: Binge Eating Frequency (Continuous) — 0.8; 12.1 Eating events/28 days — p=.0002
Phase 4 N=24 Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Subjects to Exhibit Adrenal Suppression as Measured by a Cosyntropin Stimulation Test — 6; 17 Participants
Phase 3 N=637 A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Geographic Atrophy
Primary: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — 1.5579; 1.6512; 1.9692 mm^2 — p=0.0004
Phase 3 N=1,563 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
Septic Shock
Primary: Death Before Discharge Home by Day 90 — 14; 14.9 percentage of participants — p=0.61
N/A N=1,542 Emergency Department Outcomes for Patients With Opioid Use Disorder
Opioid-use Disorder
Primary: Percent of Participants Who Received Emergency Department (ED)-Initiated/Expedited Buprenorphine (BUP) — 39.40 Percentage of participants
N/A N=91 Comparison of Hearing Aid Fitting Outcomes Between Self-fit and Professional Fit for MDHearing Smart Hearing Aids
Hearing Loss
Primary: Number of Participants With Improvement at 1 Month as Measured by the Abbreviated Profile of Hearing Aid Benefit (APHAB) and Speech Spatial Qualities 12 (SSQ 12) Scale…
Phase 2 N=20 Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV
HIV-1 Infection
Primary: Change From Baseline in Copies of HIV DNA Per CD4+ T Cell at Week 24 — 113; 98 HIV DNA copies per CD4+ T cell — p=0.0797
N/A N=60 Postpartum Weight Loss for Women at Elevated Cardiovascular Risk
Weight Loss · Postpartum Weight Retention · Hypertension in Pregnancy
Primary: Change in Weight in Pounds From Baseline to 16-week Follow-up — -8.6; -3.3 pounds — p=0.048
Phase 1 N=24 A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. — 1; 0; 0 participants
Phase 2 N=27 Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects
Chronic Kidney Disease
Primary: Change From Baseline in Mean 24-Hour Urine Total Protein Level at Week 6 — 2.07; 2.07; 1.95; -0.62 Grams per 24 hours — p=0.0040
Phase 3 N=92 Long-Term Treatment With rhIGF-1 in GHIS
Growth Hormone Insensitivity Syndrome
Primary: Annualized Height Velocity Up to 12 Years — 2.6; 8.0; 5.9; 5.5 centimeter per year (cm/y)
Phase 3 N=458 A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 435; 75…
Phase 2 N=36 Azacitidine and Pembrolizumab in Pancreatic Cancer
Pancreas Cancer
Primary: Progression-Free Survival (PFS) — 1.49 months